Japan Biosimilars: Landscape Today, Outlook Tomorrow – ‘Biosame’ entry, uninterrupted supply and companies’ strong front-end footprint requirements make it a distinct market
- After a decade, JP Biosimilar guideline’s first revision expected in FY2020 –Demonstrate Chuikyo need of biosimilar tool to curb healthcare cost - Biosimilars uptake varies as per each opportunity, Remicade BS vs. Rituxan BS- Two poles of the curve - A few skipping NHI listing due to manufacturing issues associated with constantsupply need, Japanese CDMO imminent to seal this local need Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and…